These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 29076910

  • 1. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J, Lewington V, Krolicki L.
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [Abstract] [Full Text] [Related]

  • 2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 4. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.
    Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L.
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [Abstract] [Full Text] [Related]

  • 5. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors.
    Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E, Sundlöv A, Trägårdh E.
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Dec; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 16. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [Abstract] [Full Text] [Related]

  • 17. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J.
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [Abstract] [Full Text] [Related]

  • 18. Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study.
    Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L.
    J Nucl Med; 2023 Sep; 64(9):1406-1411. PubMed ID: 37474267
    [Abstract] [Full Text] [Related]

  • 19. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB.
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
    Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A.
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.